On April 14, 2026 EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, reported that the company will be presenting a Novel Prodrug T-Cell Engager (ProTCE) Platform poster presentation at the upcoming 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place at the San Diego Convention Center in San Diego, California, from April 17-22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters will feature: ProTCE Platform and Initial Pre-clinical Proof of Concept for EM33. Details for the presentation are as follows:
ProTCE Platform and its Candidate ProTCE EM33
Title: A novel and versatile Prodrug T cell engager platform with a novel candidate demonstrating potent and tumor-restricted activity
Presentation Number: 1610
Presentation Date: Monday, April 20, 2026
Presentation Time: 9:00AM – 12:00PM, local time (Location: Poster Section 10)
"We are pleased to present our Prodrug T-cell engager technology platform at AACR (Free AACR Whitepaper) annual conference. This achievement validates the global competitiveness and clinical translation potential of our proprietary innovations, marking a key milestone in advancing the company’s R&D capabilities," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "Moving forward, the platform aims to address key unmet medical needs and advance the development of safer and more effective therapeutic options for patients worldwide."
(Press release, EpimAb Biotherapeutics, APR 14, 2026, View Source [SID1234664389])